Histone deacetylase inhibitors as a treatment of TRAIL-resistant cancers

There are no files associated with this record.

Title Histone deacetylase inhibitors as a treatment of TRAIL-resistant cancers
Author Neuzil, Jiri; Andera, Ladislav; Gabrielli, Brian
Book Title Application of apoptosis to cancer treatment
Editor Sluyser, M.
Year Published 2005
Place of publication Dordrecht
Publisher Springer
Abstract Histone deacetylas inhibitors (HDIs) are a novel prospective group of potential anti-cancer agents, some of them being tested in a clinical setting. The major mode of action of these compounds is inhibition of the cell cycle transition and, consequently, differential regulation of a number of genes necessary for cell proliferation, while favouring expression of genes rather associated with anti-proliferative pathways and with cell death signalling. This implies a possible role of HDIs in adjuvant treatment of tumours resistant to other agents, operating via a different molecular mechanism. The TNF-related apoptosis-inducing ligant (TRAIL) is a promising immunological inducer of apoptosis efficient against a variety of tumours with a remarkably selective mode of action. However, some malignancies are resistant to TRAIL treatment. In this paper, we review our current knowledge on HDI-mediated sensitisation of TRAIL-non-responsive tumours to this apoptogen and suggest a future clinical potential of HDIs and TRAIL in cancer management.
Peer Reviewed Yes
Published Yes
Alternative URI http://dx.doi.org/10.1007/1-4020-3302-8_12
Chapter Number 12
Page from 271
Page to 292
ISBN 1402033036
Date Accessioned 2009-10-09
Language en_AU
Research Centre Menzies Health Institute Qld; Molecular Basis of Disease
Faculty Griffith Health Faculty
Subject PRE2009-Cross discipline
URI http://hdl.handle.net/10072/27932
Publication Type Book Chapters
Publication Type Code b1a

Show simple item record

Griffith University copyright notice